Sonoma Pharmaceuticals (STU:O8Z) Net Change in Cash : €-0.91 Mil (TTM As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sonoma Pharmaceuticals Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Sonoma Pharmaceuticals's Net Change in Cash for the three months ended in Jun. 2024 was €-0.50 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.91 Mil.

Sonoma Pharmaceuticals Net Change in Cash Historical Data

The historical data trend for Sonoma Pharmaceuticals's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals Net Change in Cash Chart

Sonoma Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Net Change in Cash

Get a 7-Day Free Trial

0.44

2.88

-3.34

-0.64

Sonoma Pharmaceuticals Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Net Change in Cash	Get a 7-Day Free Trial															-0.26	-1.32	0.25	0.67	-0.50

Sonoma Pharmaceuticals Net Change in Cash Calculation

Sonoma Pharmaceuticals's Net Change in Cash for the fiscal year that ended in Mar. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-2.206	+	-0.002	+	1.542	+	0.029
	=	-0.64

Sonoma Pharmaceuticals's Net Change in Cash for the quarter that ended in Jun. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -0.847 + -0.005 + 0.591 + -0.24

= -0.50

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sonoma Pharmaceuticals Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Sonoma Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (STU:O8Z) » Definitions » Net Change in Cash

Comparable Companies

SHPH STEK BLMH ECGS HSTI SBFM DKSC CRYM PTPI EVOK XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XTAE:TEVA XSWX:SDZ NBIX NSE:DIVISLAB

Traded in Other Exchanges

SNOA:USA O8Z3:Germany

Address

5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301

Website

https://www.sonomapharma.com

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.

Sonoma Pharmaceuticals Headlines

No Headlines